ALK-Abelló A/S – OTC:AKABY
ALK-Abelló A/S stock price today
ALK-Abelló A/S stock price monthly change
ALK-Abelló A/S stock price quarterly change
ALK-Abelló A/S key metrics
Market Cap | 99.09B |
Enterprise value | 99.56B |
P/E | 3000 |
EV/Sales | 23.55 |
EV/EBITDA | 152.94 |
Price/Sales | 148.20 |
Price/Book | 165.46 |
PEG ratio | 3.87 |
EPS | 0.29 |
Revenue | 4.22B |
EBITDA | 651M |
Income | 318M |
Revenue Q/Q | 20.39% |
Revenue Y/Y | 15.74% |
Profit margin | 7.52% |
Oper. margin | 9.42% |
Gross margin | 62.46% |
EBIT margin | 9.42% |
EBITDA margin | 15.4% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeALK-Abelló A/S stock price history
ALK-Abelló A/S stock forecast
ALK-Abelló A/S financial statements
| Sep 2021 | 928M | 37M | 3.99% |
|---|---|---|---|
| Dec 2021 | 1.09B | 76M | 6.92% |
| Mar 2022 | 1.15B | 163M | 14.11% |
| Jun 2022 | 1.04B | 42M | 4.02% |
| Sep 2021 | 5718000000 | 2.40B | 42.04% |
|---|---|---|---|
| Dec 2021 | 5830000000 | 2.35B | 40.31% |
| Mar 2022 | 5967000000 | 2.31B | 38.73% |
| Jun 2022 | 6207000000 | 2.42B | 39% |
| Sep 2021 | 99M | -78M | -11M |
|---|---|---|---|
| Dec 2021 | 158M | -105M | -75M |
| Mar 2022 | 91M | -53M | -96M |
| Jun 2022 | 145M | -90M | 6M |
ALK-Abelló A/S alternative data
| Aug 2023 | 2,566 |
|---|---|
| Sep 2023 | 2,566 |
| Oct 2023 | 2,566 |
| Nov 2023 | 2,566 |
| Dec 2023 | 2,566 |
| Jan 2024 | 2,566 |
| Feb 2024 | 2,566 |
| Mar 2024 | 2,566 |
| Apr 2024 | 2,566 |
| May 2024 | 2,566 |
| Jun 2024 | 2,566 |
| Jul 2024 | 2,566 |
ALK-Abelló A/S other data
-
What's the price of ALK-Abelló A/S stock today?
One share of ALK-Abelló A/S stock can currently be purchased for approximately $90.
-
When is ALK-Abelló A/S's next earnings date?
Unfortunately, ALK-Abelló A/S's (AKABY) next earnings date is currently unknown.
-
Does ALK-Abelló A/S pay dividends?
No, ALK-Abelló A/S does not pay dividends.
-
How much money does ALK-Abelló A/S make?
ALK-Abelló A/S has a market capitalization of 99.09B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.17% to 3.92B US dollars.
-
What is ALK-Abelló A/S's stock symbol?
ALK-Abelló A/S is traded on the OTC under the ticker symbol "AKABY".
-
What is ALK-Abelló A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ALK-Abelló A/S?
Shares of ALK-Abelló A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ALK-Abelló A/S have?
As Jul 2024, ALK-Abelló A/S employs 2,566 workers.
-
When ALK-Abelló A/S went public?
ALK-Abelló A/S is publicly traded company for more then 11 years since IPO on 5 Sep 2013.
-
What is ALK-Abelló A/S's official website?
The official website for ALK-Abelló A/S is alk.net.
-
How can i contact ALK-Abelló A/S?
ALK-Abelló A/S can be reached via phone at +45 45 74 75 76.
ALK-Abelló A/S company profile:
ALK-Abelló A/S
alk.netOTC
2,566
Biotechnology
Healthcare
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Horsholm, 2970
:
ISIN: US0016281067
:
